Home » Authors » Brady Huggett

Articles by Brady Huggett

Igeneon Expands Celltrion Deal For Up To $20M More

Feb. 8, 2006

By Brady Huggett

Maxygen, Roche Enter $95M Recombinant Factor VIIa Deal

Dec. 16, 2005

By Brady Huggett

Maxygen, Roche Enter $95M Recombinant Factor VIIa Deal

Dec. 16, 2005

By Brady Huggett

Gauging State Of European Biotechnology VC Industry

Dec. 5, 2005

By Brady Huggett

Gauging State Of European Biotechnology VC Industry

Dec. 5, 2005

By Brady Huggett

VC Syndication Key For Young European Biotechnology Firms

Dec. 1, 2005

By Brady Huggett

VC Syndication Key For Young European Biotechnology Firms

Dec. 1, 2005

By Brady Huggett

Serenex In-Licenses Phase II Drug, Raises $30M Series C

Oct. 6, 2005

By Brady Huggett

Serenex In-Licenses Phase II Drug, Raises $30M Series C

Oct. 6, 2005

By Brady Huggett

RenaMed Forms Deal With Genzyme For Up To $43M

Sep. 29, 2005

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 27, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 27, 2024.
In muscular dystrophies, gene therapies race the clock
BioWorld
Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...
Bridgebio, with FDA approval, faces Pfizer in ATTR
BioWorld
With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...
‘Evo’ AI can design complete genomes
BioWorld Science
The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.